Cargando…

Principles for consistent value assessment and sustainable funding of orphan drugs in Europe

The European Orphan Medicinal Products (OMP) Regulation has successfully encouraged research to develop treatments for rare diseases resulting in the authorisation of new OMPs in Europe. While decisions on OMP designation and marketing authorisation are made at the European Union level, reimbursemen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gutierrez, Laura, Patris, Julien, Hutchings, Adam, Cowell, Warren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Position Statement
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433088/ https://www.ncbi.nlm.nih.gov/pubmed/25935555 http://dx.doi.org/10.1186/s13023-015-0269-y

Ejemplares similares

Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)
por: Annemans, Lieven, et al.
Publicado: (2017)

Registries for orphan drugs: generating evidence or marketing tools?
por: Hollak, Carla E. M., et al.
Publicado: (2020)

How to START? Four pillars to optimally begin your orphan drug development
por: Jonker, Anneliene Hechtelt, et al.
Publicado: (2023)

Orphan devices: yesterday is history; tomorrow is mystery: towards a European orphan device directive?
por: Dooms, Marc M
Publicado: (2016)

A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs
por: Cui, Yazhou, et al.
Publicado: (2015)

The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development
por: Heslop, Emma, et al.
Publicado: (2015)

Orphan medical devices have come a long way
por: Dooms, M.
Publicado: (2023)

Rare disease education in Europe and beyond: time to act
por: Tumiene, Birute, et al.
Publicado: (2022)

European principles of inhibitor management in patients with haemophilia
por: Giangrande, P. L. F., et al.
Publicado: (2018)

The first European consensus on principles of management for achondroplasia
por: Cormier-Daire, Valerie, et al.
Publicado: (2021)

Fundamental principles of an effective diabetic retinopathy screening program
por: Lanzetta, Paolo, et al.
Publicado: (2020)

Optimising the diagnosis and referral of achondroplasia in Europe: European Achondroplasia Forum best practice recommendations
por: Cormier-Daire, Valerie, et al.
Publicado: (2022)

European Achondroplasia Forum guiding principles for the detection and management of foramen magnum stenosis
por: Irving, Melita, et al.
Publicado: (2023)

Gaps in the evidence underpinning high-risk medical devices in Europe at market entry, and potential solutions
por: Hulstaert, Frank, et al.
Publicado: (2023)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Cross-cutting view of current challenges in paediatric solid organ and haematopoietic stem cell transplantation in Europe: the European Reference Network TransplantChild
por: Jara, P., et al.
Publicado: (2020)

Data silos are undermining drug development and failing rare disease patients
por: Denton, Nathan, et al.
Publicado: (2021)

Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases
por: Douglas, Conor M. W., et al.
Publicado: (2022)

AOASM Position Statement on Esports, Active Video Gaming, and the Role of the Sports Medicine Physician
por: Franks, R. Robert, et al.
Publicado: (2022)

Society for Cardiovascular Magnetic Resonance (SCMR) guidance for the practice of cardiovascular magnetic resonance during the COVID-19 pandemic
por: Han, Yuchi, et al.
Publicado: (2020)

French recommendations for the management of Behçet’s disease
por: Kone-Paut, Isabelle, et al.
Publicado: (2021)

French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes
por: Groh, Matthieu, et al.
Publicado: (2023)

Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III
por: Ghosh, Arunabha, et al.
Publicado: (2017)

Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability
por: Clayton-Smith, Jill, et al.
Publicado: (2019)

UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2
por: Hanson, Helen, et al.
Publicado: (2023)

Turner syndrome: French National Diagnosis and Care Protocol (NDCP; National Diagnosis and Care Protocol)
por: Fiot, Elodie, et al.
Publicado: (2022)

Position Statements
Publicado: (2009)

Diabetes Care in the School and Day Care Setting
Publicado: (2009)

Third-Party Reimbursement for Diabetes Care, Self-Management Education, and Supplies
Publicado: (2009)

Diagnosis and Classification of Diabetes Mellitus
Publicado: (2009)

Diabetes Management in Correctional Institutions
Publicado: (2009)

Diabetes and Employment
Publicado: (2009)

Standards of Medical Care in Diabetes—2009
Publicado: (2009)

Regulation of Glucose Control in People with Type 2 Diabetes: A Review and Consensus
por: Woo, Jeong-Taek, et al.
Publicado: (2010)

Diabetes Management in Correctional Institutions
Publicado: (2011)

Position Statements
Publicado: (2011)

Diabetes and Employment
Publicado: (2011)

Standards of Medical Care in Diabetes—2011
Publicado: (2011)

Diagnosis and Classification of Diabetes Mellitus
Publicado: (2011)

Third-Party Reimbursement for Diabetes Care, Self-Management Education, and Supplies
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_s7f5h6vseg5n22e680t2k46o0u